Skip to main content
OpenTrials
Completed

NCT Number: NCT04185012

NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab

Background and rationale:

Phase III-b study.

Population and patient selection criteria: Adult patients with Chronic Rhinosinusitis with Nasal Polyps (allergic and non-allergic) requiring at least 1000 mg oral prednisone over the previous twelve months to control symptoms of rhinosinusitis, and with:

* Nasal polyps score (Meltzer et al.) ≥ 5 * Symptoms VAS scores (for nasal obstruction, hyposmia, post-nasal drip, sneezing, rhinorrea; 0-10 for each symptom) > 24 Sample size: 20 subjects.

Study design and study duration:

This is a pilot, prospective, double-blind placebo-controlled (DBPC) phase III-b trial with Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks (followed up at 32 and 52 weeks) in patients with chronic rhinosinusinusitis with nasal polyps (CRSwNP).

Description of study treatment/product/intervention: Benralizumab, 30 mg subcutaneously every 4 week for the first 3 doses, and then every 8 weeks.

Objectives:

* Primary objective: To assess the clinical efficacy of Benralizumab on CRSwNP at week 24 (vs baseline) after the beginning of treatment, and to correlate the presence of baseline biomarkers with nasal polyp (NP) score improvement, in order to identify any possible predictive biomarker of response to Benralizumab. * Secondary objective: In the follow up phase we will monitor all the biomarkers at 32 and 52 weeks , this monitoring will ascertain if any of those will predict relapse of nasal polyps and consequently when Benralizumab treatment has to be reinstalled. * Safety objective: To evaluate the safety and tolerability of Benralizumab in patients with CRSwNP

Statistical methods, data analysis: Descriptive analysis of all collected variables at all time-points will be performed. Patients will be classified into "responders" and "non responders", for primary endopoint variable. Continuous variables will be evaluated with the normality test of Kolmogorov-Smirnov and compared with ANOVA or the Mann-Whitney test, depending on the normality of distribution. Categorical variables will be compared using Fisher's exact test.

Ethical considerations: The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, applicable regulatory requirements and the Sponsor policy on Bioethics and Human Biological Samples.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasal Polyps Nose Diseases Otorhinolaryngologic Diseases Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Polyps Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Humanitas Clinical and Research Hospital

Rozzano, MI, 20089, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients with Chronic Rhinosinusitis with Nasal Polyps (allergic and non-allergic) requiring at least 1000 mg oral prednisone over the previous twelve months to control symptoms of rhinosinusitis, and with:

  • Nasal polyps score (Meltzer et al.) > 5
  • Symptoms VAS scores (for nasal obstruction, hyposmia, post-nasal drip, sneezing, rhinorrea; 0-10 for each symptom) > 24
  • Provision of informed consent prior to any study specific procedure

Exclusion criteria

  • Patients < 18 years age
  • Pregnant women
  • Biologic therapy in the past 6 months (or at least a period corresponding to 5 half-life of used drugs) (eg: omalizumab, mepolizumab, reslizumab, dupilumab)
  • Previous treatment with Benralizumab
  • Known hypersensitivity to benralizumab or any of its excipients
  • Immunosuppression other than oral steroids in the past 3 months
  • Allergen immunotherapy in the past 6 months
  • Serious life threatening cardiopulmonary disorders
  • Systemic immunologic disorder in the last 12 months
  • Positive history for malignant tumors ever in patient's life
  • Patients with conditions or concomitant diseases making them non evaluable at visit 1 or for the primary efficacy endpoint:
  • Ongoing rhinitis medicamentosa
  • Nasal septal deviation occluding at least one nostril
  • Acute sinusitis, nasal infection, upper respiratory infections
  • Radiologic suspicion or confirmed invasive or expansive fungal rhinosinusitis
  • Eosinophilic Granulomatosis with Polyangiitis (previously named Churg-Strauss Syndrome)
  • Granulomatosis with Polyangiitis (previously named Wegener's granulomatosis)
  • Young's Syndrome
  • Kartagener's Syndrome
  • all ciliary dyskinesia
  • Cystic Fibrosis
  • Systemic corticosteroid treatment for other chronic conditions (i.e.: autoimmune disorders, tumors,….)
  • Evidence of active systemic immunedepression (i.e..: primary or secondary immunodeficiency)
  • Patients with severe asthma, defined according to ERS/ATS definition

Treatment and study plan

Benralizumab

Biological

Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period

Placebo

Biological

Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period

Primary outcomes

  1. Significant reduction of the Nasal polyps Score (range: 0-8; higher values mean larger nasal polyps size)

    Time frame: at week 24 (vs baseline)

    score reduction of 1.5

Secondary outcomes

  1. Reduction in Lund-MacKay Score (range: 0-24; higher values mean larger nasal polyps extension)

    Time frame: at week 24 (vs baseline)

    >50% of baseline

  2. Improvement of Sino-Nasal Outcome Test (SNOT-22; range: 0-110; higher values mean poorer disease-related quality of life)

    Time frame: at week 24 (vs baseline)

    >40% of baseline

  3. Improvement of smell Visual Analogue Scale (VAS; range: 0-10; higher values mean worse smell)

    Time frame: at week 24 (vs baseline)

    >50% of baseline

Sponsors and collaborators

Lead sponsor

Humanitas Clinical and Research Center

Other

Collaborators

  • AstraZeneca

Registry information

Acronym: NAPPREB

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Dec 4, 2019
Registry last updated
Oct 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.